Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Xenetic Biosciences, Inc. (XBIO) is a Biotechnology company based in US with a market capitalization of $5.1M. Revenue grew 19.0% year-over-year and free cash flow was negative at -$2.3M. This page tracks XBIO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 2 employees · IPO Jun 30, 2016

Valuation

Valuation & price

$3.04as of May 17, 2026· -70.6% vs 52w high

P/E ratio

Latest-FY diluted EPS

0.69

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$9.46$5.74$2.02Jul 25Jan 26Jul 26
$2.0252-week range$10.36
Loading valuation history…

Fundamentals

Key fundamentals

$5.1M

Market cap

19.0%

Revenue growth (YoY)

100.0%

Gross margin

-$2.3M

Free cash flow (USD)

-$7.9M

Net debt

Net cash position

10.4%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$3M$3M

Free cash flow by year

20162025

-$8.8M-$2.3M

Gross margin by year

20212025

100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventMay 13, 2026Filing

    Earnings Release

  • Quarterly reportMay 12, 2026Filing

    10-Q Filed

  • 8-K eventApr 24, 2026Filing

    Restricted Stock Award

  • Annual reportApr 24, 2026Filing

    10-K Filed

Questions

Frequently asked questions

What is Xenetic Biosciences, Inc.'s market cap?

Xenetic Biosciences, Inc. (XBIO) has a market capitalization of $5.1M.

What is XBIO's P/E ratio?

A meaningful P/E ratio is not available for XBIO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is XBIO's price-to-book (P/B) ratio?

XBIO trades at 0.69 times book value per share.

Are insiders buying XBIO stock?

SEC Form 4 filings show no open-market insider buys at Xenetic Biosciences, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.